ArticleBMJ case reports2023
Primary angiosarcoma of the breast in an early adolescent female.
Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary angiosarcoma of the breast is a rare and aggressive malignancy, which arises from endothelial cells lining blood vessels. It represents less than 0.05% of all breast cancers, and more commonly affects relatively younger individuals. Reaching the correct diagnosis may be delayed, because imaging is not typical of other breast malignancies and can mimic benign processes. Clinical presentation is variable, ranging from diffuse breast oedema to a palpable discrete mass. An early adolescent female presented to her general practitioner with a palpable breast lump on self-examination. The diagnosis of primary breast angiosarcoma was confirmed on biopsy. She underwent a complete surgical resection and adjuvant chemotherapy. She remains in remission after 3 years and is undergoing regular surveillance. Due to the rarity of this condition, there is no established clinical management protocol for this condition currently. Early detection, aggressive treatment and ongoing surveillance provide the best chance of prolonged disease-free survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.